FRATES JAMES M, CFO, reported an open-market or private sale at Amylyx Pharmaceuticals, Inc. involving 3326.000000 shares for an estimated $36953.86. Reported holdings after the transaction were 177104.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the di…
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.99 to $11.16. Full information regarding the number of shares sold…
On December 15, 2025, the Reporting Person contributed 100,000 shares of Issuer common stock to a grantor retained annuity trust for no consideration. Shares held by the JAMES M. FRATES 2025 GRAT NO 1…
0 other filings
0 recent txs